ライフサイエンスコーパス: toxin-neutralizing

1 studies demonstrated that both MAPs elicited toxin-neutralizing Ab in rabbits.

2 V230-Ficoll induced 10-fold higher titers of toxin-neutralizing Abs in cynomolgus monkeys at 2 wk com

3 to induce serum LF-specific IgG2c and lethal toxin-neutralizing Abs was significantly impaired in CD1

4 F-specific serum IgG, IgG subclasses, lethal toxin-neutralizing Abs, and mucosal IgA compared with WT

5 ve established an in vitro assay to test the toxin-neutralizing activities of antimalarial antibodies

6 l antibodies that differ in their respective toxin-neutralizing activities.

7 terized for their binding affinity and their toxin neutralizing activity in vitro and in vivo.

8 Anti-PA IgG levels and serum toxin neutralizing activity were strongly associated (R2

9 topes adjacent to V5E1 but display only weak toxin neutralizing activity, thereby providing structura

10 ngineering is a feasible strategy to enhance toxin-neutralizing activity and suggest that engineered

11 a peptide linkers have proven to have potent toxin-neutralizing activity in vivo against Shiga, botul

12 Two mAbs with toxin-neutralizing activity recognized two different epi

13 In some cases, such toxin-neutralizing activity was notably high, indicating

14 odimer D10/B7, a 6-fold increase in in vitro toxin-neutralizing activity.

15 hat any of the BoNT/A binding agents possess toxin-neutralizing activity.

16 e ricin-specific VHHs we identified, six had toxin-neutralizing activity: five specific for RTA and o

17 A single toxin-neutralizing agent consisting of a double-tagged V

18 n be promoted by coadministering a VHH-based toxin-neutralizing agent with an antitag monoclonal anti

19 VHH heterodimer toxin-neutralizing agents containing two linked Stx1-neu

20 b substantially improved the efficacy of Stx toxin-neutralizing agents to prevent death or kidney dam

21 verexpress StxB induced high titers of Shiga toxin neutralizing antibodies.

22 piglets given the toxigenic strain developed toxin-neutralizing antibodies (indicating that toxin is

23 Serologic changes, levels of toxin-neutralizing antibodies (TNAs), and pulmonary and

24 Efforts to develop toxin-neutralizing antibodies as adjunctive therapies ar

25 Toxin-neutralizing antibodies fractionated from egg yolk

26 effective in protecting animals and elicits toxin-neutralizing antibodies in humans, but enthusiasm

27 rotection was associated with high levels of toxin-neutralizing antibodies in serum.

28 High-affinity toxin-neutralizing antibodies may be of therapeutic valu

29 In previous studies, we demonstrated that toxin-neutralizing antibodies target four spatially dist

30 We have engineered a panel of toxin-neutralizing antibodies, including single-chain va

31 -Asp mutant rPA, as measured by induction of toxin-neutralizing antibodies, was significantly lower t

32 tigens, including high levels of anti-PA and toxin-neutralizing antibodies.

33 eceived low doses of BL22 or had preexisting toxin-neutralizing antibodies.

34 each toxin was most effective in generating toxin-neutralizing antibodies.

35 the in vitro and in vivo activity of anthrax toxin-neutralizing antibodies.

36 que sera from all immunized groups contained toxin-neutralizing antibody and recognized all the domai

37 significant correlation was observed between toxin-neutralizing antibody titer and survival after cha

38 e compared serum immunoglobulin G levels and toxin-neutralizing antibody titers in rabbits following

39 acis resulted in significantly higher lethal toxin-neutralizing antibody titers than did intramuscula

40 gene that suppresses bacterial growth and a toxin-neutralizing antitoxin gene, usually encoded in a

41 FI-29, a serogroup O107/O117 strain, as the toxin-neutralizing component.

42 Key toxin-neutralizing epitopes have been found within the c

43 been identified; however, the major anthrax toxin-neutralizing humoral responses to these antigens a

44 Adding plaque toxin-neutralizing MAb 3hE5 blocked the toxic effect of

45 or Sterne spore vaccine, as well as those of toxin-neutralizing monoclonal antibodies (MAbs) produced

46 y effects, HNP-1-HNP-3 possess antiviral and toxin-neutralizing properties.

47 nization also produced high titers of lethal-toxin-neutralizing serum antibodies in both mice and gui

48 l infection, supporting a potential role for toxin-neutralizing therapy.

49 30,000 (range, 5,800 to 157,000) and lethal-toxin-neutralizing titers greater than 16,000.

50 Antibodies with high toxin-neutralizing titers were generated against C. diff

51 neutralizing agent) consisting of two linked toxin-neutralizing VHHs, JMN-D10 and JMO-G1, was fully p